Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Enlivex Therapeutics Ltd 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 ISR

P: 972-2620-8072 F: 972-267-0807

Description:

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.

Key Statistics

Overview:

Market Capitalization, $K 71,571
Shares Outstanding, K 13,428
Annual Sales, $ 0 K
Annual Net Income, $ -9,380 K
60-Month Beta 1.92
% of Institutional Shareholders 7.15%
Float, K 13,428
% Float 100.00%

Growth:

1-Year Return -75.50%
3-Year Return -78.85%
5-Year Return -97.56%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 95.13%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/07/20
Earnings Per Share ttm -0.58
EPS Growth vs. Prev Qtr 75.00%
EPS Growth vs. Prev Year 90.54%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-8 on 03/06/19

ENLV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -41.46%
Return-on-Assets % -31.55%
Profit Margin % N/A
Net Margin % N/A
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.29
Book Value/Share 0.00
Interest Coverage -8.38
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar